article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Endovascular therapy improves left ventricular diastolic function in heart failure with preserved ejection fraction

Medical Xpress - Cardiology

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ventricular (LV) diastolic function, according to a study published online Sept. 9 in Circulation: Heart Failure.

article thumbnail

Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting

Circulation

Circulation, Ahead of Print.

article thumbnail

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF

Circulation: Heart Failure

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010633, November 1, 2023. BACKGROUND:Heart failure with preserved ejection fraction is associated with significant functional limitations, yet treatments for improving exercise performance have been elusive.

article thumbnail

Palliative Care for Patients With Heart Failure With Preserved Ejection Fraction

Circulation: Heart Failure

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010802, November 1, 2023. Heart failure with preserved ejection fraction (HFpEF) has become the leading form of heart failure worldwide, particularly among elderly patient populations.

article thumbnail

Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials

Circulation

Circulation, Ahead of Print. BACKGROUND:Sodium-glucose cotransporter 2 inhibitors reduce the risk of worsening heart failure (HF) and cardiovascular death in patients with HF irrespective of left ventricular ejection fraction. Dapagliflozin did not improve these outcomes in patients with HF with preserved ejection fraction.

article thumbnail

Modeling Heart Failure With Preserved Ejection Fraction Using Human Induced Pluripotent Stem Cell–Derived Cardiac Organoids

Circulation: Heart Failure

Circulation: Heart Failure, Ahead of Print. BACKGROUND:The therapeutic armamentarium for heart failure with preserved ejection fraction (HFpEF) remains notably constrained.